Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event

Rhea-AI Summary

Aeterna Zentaris Inc. (NASDAQ: AEZS) will host a live video webcast presentation on January 19, 2023, at 3:00 PM ET during the Virtual Investor 2023 Companies to Watch Event. The presentation will be led by Dr. Klaus Paulini, CEO, and will be available on the Company’s website, with a replay accessible for 90 days. Aeterna focuses on developing pharmaceutical and diagnostic products for unmet medical needs, notably through its lead product, macimorelin, an FDA-approved oral test for diagnosing adult growth hormone deficiency.

Live video webcast on Thursday, January 19^th at 3:00 PM ET

TORONTO, ONTARIO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the Virtual Investor 2023 Companies to Watch Event on Thursday, January 19, 2023 at 3:00 PM ET.

A live video webcast of the presentation will be available on the Events page of the Company’s website (www.zentaris.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen^™; Ghryvelin^®), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD), an area of significant unmet need, in collaboration with Novo Nordisk.

Aeterna Zentaris is dedicated to the development of therapeutic assets and has recently taken steps to establish a growing pre-clinical pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease). Additionally, the Company is developing an oral prophylactic bacterial vaccine against SARS-CoV-2 (COVID-19) and Chlamydia trachomatis.

For more information, please visit www.zentaris.com and connect with the Company on Twitter, LinkedIn and Facebook.

Investor Contact:

Jenene Thomas
JTC Team
T (US): +1 (833) 475-8247
E: aezs@jtcir.com

FAQ

What is the date and time of the Aeterna Zentaris presentation?

The Aeterna Zentaris presentation is scheduled for January 19, 2023, at 3:00 PM ET.

Who will present at the Virtual Investor event?

Dr. Klaus Paulini, the CEO of Aeterna Zentaris, will present at the event.

Where can I watch the Aeterna Zentaris presentation?

The presentation can be viewed live on the Company’s website, with a replay available for 90 days.

What is Aeterna Zentaris known for?

Aeterna Zentaris is known for developing macimorelin, the first oral test approved for adult growth hormone deficiency.

What are Aeterna Zentaris's primary areas of focus?

Aeterna Zentaris focuses on unmet medical needs, including growth hormone deficiencies and neurological disorders.